ATE282413T1 - Verwendung von tempol zur behandlung von essentiellem hochdruck - Google Patents

Verwendung von tempol zur behandlung von essentiellem hochdruck

Info

Publication number
ATE282413T1
ATE282413T1 AT98947159T AT98947159T ATE282413T1 AT E282413 T1 ATE282413 T1 AT E282413T1 AT 98947159 T AT98947159 T AT 98947159T AT 98947159 T AT98947159 T AT 98947159T AT E282413 T1 ATE282413 T1 AT E282413T1
Authority
AT
Austria
Prior art keywords
tempol
essential hypertension
treat essential
compositions
treat
Prior art date
Application number
AT98947159T
Other languages
English (en)
Inventor
Christopher S Wilcox
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE282413T1 publication Critical patent/ATE282413T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Steroid Compounds (AREA)
AT98947159T 1997-09-19 1998-09-21 Verwendung von tempol zur behandlung von essentiellem hochdruck ATE282413T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/933,379 US6096759A (en) 1997-09-19 1997-09-19 Method for treating essential hypertension
PCT/US1998/019586 WO1999013875A1 (en) 1997-09-19 1998-09-21 Use of nitroxides for the treatment of essential hypertension

Publications (1)

Publication Number Publication Date
ATE282413T1 true ATE282413T1 (de) 2004-12-15

Family

ID=25463831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98947159T ATE282413T1 (de) 1997-09-19 1998-09-21 Verwendung von tempol zur behandlung von essentiellem hochdruck

Country Status (6)

Country Link
US (2) US6096759A (de)
EP (1) EP1014980B1 (de)
AT (1) ATE282413T1 (de)
AU (1) AU9400498A (de)
DE (1) DE69827651T2 (de)
WO (1) WO1999013875A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6428822B1 (en) 2001-04-03 2002-08-06 Chengzhi Life Science Company, Ltd. Extracts of mixed arctium lappa L., carrot and whole radish for treating hypertension, constipation and detoxification
US20050187468A1 (en) * 2001-11-29 2005-08-25 Atlas Glen M. Modified esophageal doppler monitor methods for measuring aortic dp/dt and pulse wave velocity
EP1938798A1 (de) 2002-02-22 2008-07-02 Schering Corporation Pharmazeutische Formulierungen aus antineoplastischen Wirkstoffen, insbesondere Temozolomiden, sowie Herstellungs- und Verwendungsverfahren dafür
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
AU2004216541A1 (en) * 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
EP1732577B1 (de) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topische verabreichung von l-arginin zur verbesserung des aussehens von körper und haut
US9050365B2 (en) 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
WO2006020912A2 (en) * 2004-08-11 2006-02-23 The Regents Of The University Of California Treatments for congestive heart failure
US20090062338A1 (en) * 2005-02-02 2009-03-05 Louis Habash Nitroxides for use in treating or preventing cardiovascular disease
US8563581B2 (en) * 2005-02-02 2013-10-22 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating predisposed or at risk patients
JP2008528703A (ja) * 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド アミロイド関連疾患の治療又は予防に用いるためのニトロキシド類
CA2605150A1 (en) * 2005-04-14 2006-10-26 Cary Pharmaceuticals Combination formulation
WO2007145938A2 (en) * 2006-06-06 2007-12-21 Braginsky Philip Y Beverages containing pheromone component
US20080015224A1 (en) * 2006-06-26 2008-01-17 Christopher Wilcox Nitroxide superoxide dismutase mimetics to treat extracellular superoxide dismutase deficiencies
EP3045171A1 (de) * 2009-06-24 2016-07-20 Strategic Science & Technologies, LLC Topische zusammensetzung
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US20110130421A1 (en) * 2009-10-29 2011-06-02 Georgetown University Methods and Compositions for the Treatment of Chronic Renal Hypertension
US8778969B2 (en) 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
WO2012078587A1 (en) * 2010-12-07 2012-06-14 University Of Oslo Cardio-protective agents from kiwifruits
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
CN105920603B (zh) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
US20140275166A1 (en) * 2013-03-15 2014-09-18 Peter Herbert Proctor Spintraps and spin labels and their hydroxylamines for peri- and post-menopausal syndrome
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
US20180078539A1 (en) * 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
WO2019100008A1 (en) * 2017-11-20 2019-05-23 Georgetown University Treatments and methods for controlling hypertension
US12208089B2 (en) * 2021-05-25 2025-01-28 Louis Habash Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310761A1 (fr) * 1975-05-16 1976-12-10 Roussel Uclaf Nouveaux derives de la phenyl-piperidine et leurs sels, procede de preparation et application a titre de medicaments
JPS60120861A (ja) * 1983-12-02 1985-06-28 Otsuka Pharmaceut Co Ltd ジヒドロピリジン誘導体
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US5716947A (en) * 1985-07-18 1998-02-10 Proctor; Peter H. Topical doxyl composition and method
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
DK0787492T3 (da) * 1990-03-16 2004-02-02 Us Secretary United States Dep Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress
US5280015A (en) * 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
WO1992022290A1 (en) * 1991-06-18 1992-12-23 Oklahoma Medical Research Foundation Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins
JP3490442B2 (ja) * 1992-09-25 2004-01-26 ベーリンガー インゲルハイム （カナダ） リミテッド レニン阻害ｎ−（２−アミノ−２−オキソエチル）ブタンジアミド誘導体
GB9220735D0 (en) * 1992-10-02 1992-11-18 British Tech Group Heterocyclic amines
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5516881A (en) * 1994-08-10 1996-05-14 Cornell Research Foundation, Inc. Aminoxyl-containing radical spin labeling in polymers and copolymers
WO1998053835A1 (en) * 1997-05-27 1998-12-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Also Published As

Publication number Publication date
WO1999013875A8 (en) 1999-05-27
DE69827651T2 (de) 2005-10-06
WO1999013875A1 (en) 1999-03-25
EP1014980A1 (de) 2000-07-05
AU9400498A (en) 1999-04-05
DE69827651D1 (de) 2004-12-23
US6617337B1 (en) 2003-09-09
US6096759A (en) 2000-08-01
EP1014980B1 (de) 2004-11-17

Similar Documents

Publication Publication Date Title
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE259650T1 (de) Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
DE60239612D1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE247968T1 (de) Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties